No association between triple‑negative breast cancer and prognosis of patients receiving breast‑conserving treatment

Mu,Lan; Liu,Yuxiang; Xiao,Meng; Liu,Weise; Liu,Miao; Wang,Xin

doi:10.3892/ol.2017.7251

No association between triple‑negative breast cancer and prognosis of patients receiving breast‑conserving treatment

Authors:
- Lan Mu
- Yuxiang Liu
- Meng Xiao
- Weise Liu
- Miao Liu
- Xin Wang
View Affiliations

Affiliations: First Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormones and Development (Ministry of Health), Metabolic Diseases Hospital, Tianjin Medical University, Tianjin 300070, P.R. China
Published online on: October 23, 2017 https://doi.org/10.3892/ol.2017.7251
Pages: 7862-7872
Copyright: © Mu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of triple‑negative breast cancer (TNBC) in breast‑conserving treatment is controversial. The present study aimed at evaluating the prognosis of patients with TNBC following breast‑conserving treatment (BCT) within 5 years. The present study investigated a cohort of 757 patients with early stage breast cancer, diagnosed and treated with BCT between January 2002 and March 2010 at Tianjin Medical University Cancer Institute and Hospital. The patients were divided into three groups according to receptor expression: Estrogen receptor (ER) or progesterone receptor (PR)‑positive; epidermal growth factor receptor 2 (HER2)‑enriched: ER and PR negative but HER2‑positive; TNBC: ER, PR and HER2 receptor‑negative. The primary endpoint was recurrence or mortality within 5 years after breast cancer diagnosis. Multivariable Cox analysis was used to determine the risk of locoregional relapse, distant metastases, total relapse and mortality associated with the intrinsic subtypes. Of the 757 patients with status of all receptors available, 541 (71.5%) were luminal, 66 (8.7%) were HER2‑enriched and 150 (19.8%) were TNBC. Patients with TNBC were more likely to have histological grade III tumors (27.3%) compared with luminal (8.3%) and HER2‑enriched (16.7%) subtypes (P<0.001). Within 5 years, locoregional recurrence rate was 2.4, 7.6 and 7.3% for luminal, HER2‑enriched and TNBC, respectively (P=0.005). Mortality rate was 2.2, 9.1 and 4.7% for luminal, HER2‑enriched and TNBC, respectively (P=0.007). There was no significant difference in rates of distant metastases (P=0.164) and total relapse (P=0.138). TNBC was not an independent prognostic predictor for women treated with BCT within 5 years after breast cancer diagnosis on multivariate analysis. Patients with TNBC were not at significantly increased 5‑year risks of locoregional recurrence, distant metastasis, total relapse or mortality at so remain appropriate candidates for BCT.

View Figures

View References

1	Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T and Morrow M: Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol. 16:2705–2710. 2009. View Article : Google Scholar : PubMed/NCBI
2	Perou CM: Molecular stratification of triple-negative breast cancers. Oncologist. 1 16 Suppl:S61–S70. 2011. View Article : Google Scholar
3	Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
4	Abramson VG, Lehmann BD, Ballinger TJ and Pietenpol JA: Subtyping of triple-negative breast cancer: Implications for therapy. Cancer. 121:8–16. 2015. View Article : Google Scholar : PubMed/NCBI
5	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl JMed. 363:1938–1948. 2010. View Article : Google Scholar
6	Brenton JD, Carey LA, Ahmed AA and Caldas C: Molecular classification and molecular forecasting of breast cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360. 2005. View Article : Google Scholar : PubMed/NCBI
7	Pignol JP, Rakovitch E and Olivotto IA: Is breast conservation therapy superior to mastectomy for women with triple-negative breast cancers? J Clin Oncol. 29:2841–2843. 2011. View Article : Google Scholar : PubMed/NCBI
8	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM and Overgaard J; Danish Breast Cancer Cooperative Group, : Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The danish breast cancer cooperative group. J Clin Oncol. 26:1419–1426. 2008. View Article : Google Scholar : PubMed/NCBI
10	Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010. View Article : Google Scholar : PubMed/NCBI
11	Gabos Z, Thoms J, Ghosh S, Hanson J, Deschenes J, Sabri S and Abdulkarim B: The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat. 124:187–194. 2010. View Article : Google Scholar : PubMed/NCBI
12	van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K and Bartelink H: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst. 92:1143–1150. 2000. View Article : Google Scholar : PubMed/NCBI
13	Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M and Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 347:1227–1232. 2002. View Article : Google Scholar : PubMed/NCBI
14	Lazovich D, Solomon CC, Thomas DB, Moe RE and White E: Breast conservation therapy in the United States following the 1990 national institutes of health consensus development conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 86:628–637. 1999. View Article : Google Scholar : PubMed/NCBI
15	Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL and Harris JR: Breast cancer subtype approximated by estrogen receptor, progesterone receptor and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 26:2373–2378. 2008. View Article : Google Scholar : PubMed/NCBI
16	Solin LJ, Hwang WT and Vapiwala N: Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer. 9:96–100. 2009. View Article : Google Scholar : PubMed/NCBI
17	Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
18	Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, Eggleton S, Beretov J, Theocharous C, Capp A, et al: Prediction of local recurrence, distant metastases and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 27:4701–4708. 2009. View Article : Google Scholar : PubMed/NCBI
19	Gangi A, Chung A, Mirocha J, Liou DZ, Leong T and Giuliano AE: Breast-conserving therapy for triple-negative breast cancer. JAMA Surg. 149:252–258. 2014. View Article : Google Scholar : PubMed/NCBI
20	Connolly JL: Changes and problematic areas in interpretation of the AJCC cancer staging manual, 6th edition, for breast cancer. Arch Pathol Lab Med. 130:287–291. 2006.PubMed/NCBI
21	Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
22	Tummaruk P, Tienthai P, Manee-In S and Srisuwatanasagul S: Expression of progesterone receptor in the utero-tubal junction after intra-uterine and deep intra-uterine insemination in sows. Reprod Domest Anim. 45:e26–e31. 2010.PubMed/NCBI
23	Cejalvo JM, Martínez de Dueñas E, Galván P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, et al: Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res. 77:2213–2221. 2017. View Article : Google Scholar : PubMed/NCBI
24	Kaplan HG, Malmgren JA and Atwood M: T1N0 triple negative breast cancer: Risk of recurrence and adjuvant chemotherapy. Breast J. 15:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
25	Noh JM, Choi DH, Huh SJ, Park W, Yang JH, Nam SJ, Im YH and Ahn JS: Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. J Breast Cancer. 14:46–51. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kim JY, Chang SK, Park H, Lee BM and Shin HS: Treatment outcome in patients with triple negative early stage breast cancers compared with other molecular subtypes. Radiat Oncol J. 30:124–131. 2012. View Article : Google Scholar : PubMed/NCBI
27	Freedman GM, Anderson PR, Li T and Nicolaou N: Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 115:946–951. 2009. View Article : Google Scholar : PubMed/NCBI
28	Braunstein LZ, Niemierko A, Shenouda MN, Truong L, Sadek BT, Abi Raad R, Wong JS, Punglia RS, Taghian AG and Bellon JR: Outcome following local-regional recurrence in women with early-stage breast cancer: Impact of biologic subtype. Breast J. 21:161–167. 2015. View Article : Google Scholar : PubMed/NCBI
29	Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D and Sabri S: Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 29:2852–2858. 2011. View Article : Google Scholar : PubMed/NCBI
30	Wang J, Shi M, Ling R, Xia Y, Luo S, Fu X, Xiao F, Li J, Long X, Wang J, et al: Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: A prospective randomized controlled multi-center trial. Radiother Oncol. 100:200–204. 2011. View Article : Google Scholar : PubMed/NCBI
31	Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, et al: Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 working group statement. Ann Oncol. 23:2997–3006. 2012. View Article : Google Scholar : PubMed/NCBI
32	Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A and Reis-Filho JS: Breast cancer molecular profiling with single sample predictors: A retrospective analysis. Lancet Oncol. 11:339–349. 2010. View Article : Google Scholar : PubMed/NCBI
33	Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011. View Article : Google Scholar : PubMed/NCBI
34	Eiermann W and Vallis KA: Locoregional treatments for triple-negative breast cancer. Ann Oncol. 23 Suppl 6:vi30–vi34. 2012. View Article : Google Scholar : PubMed/NCBI
35	Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 100:pp. 10393–10398. 2003; View Article : Google Scholar : PubMed/NCBI